

**CLEANSING NOTICE ISSUED UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT**

**31 August 2022 - Nutritional Growth Solutions Ltd. ("the Company" or "NGS", ASX:NGS)** a global nutrition company that creates scientifically formulated and clinically studied products to support growth development in children, issued 28,583,333 fully paid ordinary shares on 31 August 2022 ("**Shares**") as set out in the Appendix 2A lodged today.

This notice is being given under section 708A(5)(e) of the Corporations Act 2001 (Cth) ("**Corporations Act**") and the Company advises that:

1. the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
  - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - b. section 674 of the Corporations Act; and
3. as at the date of this notice there is no information that is "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Corporations Act.

-ENDS-

*This announcement has been authorised for release by the Board of Directors of Nutritional Growth Solutions Ltd.*

-ends-

For more information:

Liron Fendell  
CEO & Managing Director  
Nutritional Growth Solutions  
E: [liron@ngsolutions.co](mailto:liron@ngsolutions.co)

**Investors**

Eric Kuret  
Market Eye  
P: +61 417 311 335  
E: [eric.kuret@marketeye.com.au](mailto:eric.kuret@marketeye.com.au)

**Media**

Tristan Everett  
Market Eye  
P: +61 403 789 096  
E: [tristan.everett@marketeye.com.au](mailto:tristan.everett@marketeye.com.au)

**About Nutritional Growth Solutions**

Nutritional Growth Solutions is a global nutritional health company focused on the well-being of children. NGS develops, produces and sells clinically tested nutritional supplement formulae for children following 20 years of medical research into paediatric nutrition at Schneider Children's Medical Centre, Israel's largest paediatric hospital. The nutritional supplements market has experienced tremendous growth in recent years, but most attention has been focused on adult users and children under three years of age. The three to twelve-year-old consumers represent a larger market opportunity and NGS is highly differentiated from its competitors with clinically tested products and an expanding product portfolio to capture this market opportunity.

[ngsolutions.co](http://ngsolutions.co)